Proteomic Signature in Breast Cancer: Correlation With Tumor Response to Neo-adjuvant Chemotherapy

Analysis of the Proteomic Signature in Breast Cancer Correlated With Tumor Response in Patients Necessitating a Neo-adjuvant Chemotherapy

The scope of the trial is to identify proteomic signatures correlated with tumor response to neo-adjuvant chemotherapy.

Inclusion Criteria:

• Women aged more than 18 years
• Histologically proven breast carcinoma
• Neo-adjuvant chemotherapy with anthracyclines and/or taxanes
• No prior chemotherapy
• Written informed consent

Exclusion Criteria:

• Metastatic disease